Zhifen Chen | Public Health Analytics | Best Researcher Award

Dr. Zhifen Chen | Public Health Analytics | Best Researcher Award

German Heart Center, TUM University Hospital, Technical University of Munich (TUM) | Germany

Dr. Zhifen Chen is an Independent Junior Group Leader at the German Heart Center, Technical University of Munich, specializing in experimental cardiology. She earned her Bachelor’s degree in Life Sciences from Hubei Normal University and a Master of Science from Tsinghua University. Dr. Chen completed her PhD at the Technical University of Munich with a summa cum laude distinction, focusing on human iPSC-derived cardiomyocytes for cardiac disease modeling, therapeutic discovery, and safety pharmacology. She pursued postdoctoral research at Harvard University and the Beth Israel Deaconess Medical Center, contributing to functional genomics, CRISPR-based screening, and cardiovascular disease studies. Her research focuses on the genetics and molecular mechanisms of coronary artery disease, adipose tissue biology, insulin resistance, and cardiovascular precision medicine. Dr. Chen has secured multiple competitive grants, including from the DFG, DZHK, and international cardiovascular research partnerships. She has received numerous awards and honors, such as PhD summa cum laude, international travel awards, and conference prizes. She actively supervises postdoctoral researchers, PhD, MD, Master, and Bachelor students, and contributes to scientific communities as a reviewer, consortium member, and workshop organizer. Dr. Chen’s work integrates genome editing, transcriptomics, and advanced in vitro models to identify novel therapeutic targets, advancing cardiovascular research and translational medicine.

Profile : Orcid

Featured Publications

von Scheidt, M., Adkar, S. S., Krefting, J., Hoermann, G., Meggendorfer, M., Bauer, S., Mitchell, S., Pugach, I., Friess, C., Ma, A., et al. (2025). “Clonal Haematopoiesis of Indeterminate Potential and Mortality in Coronary Artery Disease.” European Heart Journal.

Xu, C., Nie, X., Chen, Z., Qu, J. Z., & Wang, D. (2025). “Stenotic Left Atrioventricular Valve after Atrioventricular Septal Defect Repair: A Distinct Surgical Phenotype.” The Journal of Thoracic and Cardiovascular Surgery.

Chen, Z., Li, S., Song, X., Diagel, A., Li, L., Moggio, A., Li, Z., Chen, Y., Dang, T., Li, M., et al. (2025). “An Interplay of Non-Coding RNAs Regulates CDH13 Expression and Affects Endothelial Function and Coronary Artery Disease Risk.” Preprint.

Byers, P., Kellerer, T., Li, M., Chen, Z., Huser, T., & Hellerer, T. (2025). “Super-Resolution Upgrade for Deep Tissue Imaging Featuring Simple Implementation.” Nature Communications.

Sanin, V., Schmieder, R. S., Koenig, W., Li, L., Schunkert, H., & Chen, Z. (2025). “Rolle der Genetik in der Präzisionsmedizin der Koronaren Herzkrankheit.” Herz.

Hillary Andrews | Data Analysis | Best Researcher Award

Dr. Hillary Andrews | Data Analysis | Best Researcher Award

Friends of Cancers Research | United States

Dr. Hillary S. Andrews, PhD, is a project leader and policy researcher whose scholarly output reflects strong engagement in cancer research regulation, patient-advocacy partnerships, and translational biomarker work. According to Google Scholar, she has an h-index of 7, with about 395 citations across her publications. She earned her PhD in Endocrinology and Animal Biosciences (Rutgers University, 2016), followed by a T32 NRSA postdoctoral fellowship in Tumor Biology at Georgetown University’s Lombardi Comprehensive Cancer Center. In her professional experience, she has held roles at Avalere Health (Consultant / FDA Fellow), then at Friends of Cancer Research, where she is now Director of Regulatory & Research Partnerships (since Dec 2022), after serving as Science Policy Analyst. Her work includes leading research partnerships like ctMoniTR and the HRD Harmonization Project, developing policy, authoring white-papers and peer-reviewed articles, and presenting findings at international meetings. Her research interests center on regulatory policy in oncology, translational biomarkers (e.g. HRD, circulating tumor DNA), patient access, market access pathways, and partnerships between patient advocates and researchers. Among her recognitions is authorship in high-visibility policy reports and scientific collaborations that bridge stakeholders (e.g. regulators, academia, patient advocates). In conclusion, her career demonstrates a consistent track record of integrating research, regulation, and stakeholder engagement to accelerate patient-centered cancer research and policy.

Profiles : Orcid | Google Scholar

Featured Publications

“Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends’ HRD Harmonization Project”

“Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages”

“An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022”

“Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer”

“Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality”